ProPhase Labs, Inc. (PRPH)
Market Cap | 147.43M |
Revenue (ttm) | 94.42M |
Net Income (ttm) | 6.52M |
Shares Out | 17.18M |
EPS (ttm) | 0.41 |
PE Ratio | 20.93 |
Forward PE | 10.09 |
Dividend | n/a |
Ex-Dividend Date | May 24, 2022 |
Volume | 147,769 |
Open | 9.12 |
Previous Close | 9.15 |
Day's Range | 8.47 - 9.25 |
52-Week Range | 6.60 - 15.25 |
Beta | -0.33 |
Analysts | Strong Buy |
Price Target | 14.00 (+63.17%) |
Earnings Date | May 11, 2023 |
About PRPH
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production... [Read more]
Full Company ProfileFinancial Performance
In 2022, ProPhase Labs's revenue was $122.65 million, an increase of 55.17% compared to the previous year's $79.04 million. Earnings were $18.46 million, an increase of 194.32%.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PRPH stock is "Strong Buy" and the 12-month stock price forecast is $14.0.
News

ProPhase Labs' Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testing
Linebacker fully inhibited lung cancer cell growth and significantly limited colon cancer cell growth in two separate clonogenic models

ProPhase Labs hires Dr. Matthew Halpert to Drive Company's Key Therapeutic and Diagnostic Oncology Programs
GARDEN CITY, NY, May 08, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced that Dr. Matthew Halpert has been hir...

ProPhase Labs' Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers
Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its p...

ProPhase Labs CEO Ted Karkus Named One of Inc Magazine's 10 Most Innovative Healthcare Leaders to Watch in 2023
Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, is pleased to announce that Ted Karkus...

ProPhase Labs Announces Launch of Redesigned Corporate Website
Garden City, NY, April 25, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today announced the launch of its newl...

ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022
Company highlights key strategic initiatives to grow underlying value in 2023 and beyond

ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test
Presentation to be given in Collaboration with the Mayo Clinic at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting

ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
GARDEN CITY, NY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. “ProPhase” (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it h...

ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022
GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be pres...

ProPhase Labs to Present at Investor Summit Group's Q4 Conference
GARDEN CITY, NY, Nov. 07, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participa...

ProPhase Labs to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 at 11:00 a.m. Eastern Time
GARDEN CITY, NY, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thurs...

ProPhase Labs to Present at The ThinkEquity Conference
GARDEN CITY, NY, Oct. 18, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participa...

Nebula Genomics Strengthens Advisory Board with Appointment of Russ Altman, M.D., Ph.D.
GARDEN CITY, NY, Oct. 17, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth-oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owne...

ProPhase Labs to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)
GARDEN CITY, NY, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be featured...

ProPhase Labs to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 at 11:00 a.m. Eastern Time
GARDEN CITY, NY, Aug. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thurs...

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Garden City, NY, July 21, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that it has granted an inducement stock option to...

ProPhase Labs Announces Licensing of New Investigational Cancer Compounds
Confirms Quarterly Growth continues year-over-year

ProPhase Labs Announces Formation of ProPhase BioPharma, Inc. (PBIO) for the Licensing and Development of Novel Drugs, Compounds and Biotechnology
Company Also Announces First Licensing Agreement for PBIO with Global BioLife, Inc. for broad based Anti-Viral Fighting Compounds Equivir and Equivir G

ProPhase Labs Announces Significant Laboratory Expansion
Expanding in-house clinical testing capabilities

ProPhase Labs to Present at the H.C. Wainwright 2022 Global Investment Conference
May 23-26, 2022 (HYBRID CONFERENCE)

ProPhase Labs Announces Record First Quarter 2022 Financial Results
Record Net Revenues of $47.5 Million, Up 211% Year-over-Year

ProPhase Labs to Present at the Spring Into Action – Best Ideas Virtual Investor Conference
Garden City, NY, May 11, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that Chairman and CEO Ted Karkus will present at t...

ProPhase Labs Announces Appointment of Bill White as Chief Financial Officer
Garden City, NY, May 10, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified diagnostics and genomics company, announced today that Bill White has been appointed Chief Financial...

ProPhase Labs to Host First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022 at 11:00 a.m. Eastern Time
GARDEN CITY, NY, May 06, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, will hold a conference call on Friday, May 13, 2022 at 11:00 a.m. ...

ProPhase Labs to Present at the Planet MicroCap Showcase 2022 on Wednesday, May 4, 2022
Garden City, NY, April 27, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that Chairman and CEO Ted Karkus will present a ...